No Data
Baolingbao Biology (002286.SZ): At present, allulose has been approved for use in more than a dozen countries and regions including the USA, Japan, and South Korea.
As of now, Baolingbao (002286.SZ) stated on the investor interaction platform that Alulose has not yet been approved for use in food and beverages by the European Union. Alulose has been approved for use in over a dozen countries and regions including the United States, Japan, and South Korea. Recently, the Australia and New Zealand Food Standards Agency has also approved D-Alulose as a new type of food, and the downstream customer demand will gradually increase.
Baolingbao Biology (002286.SZ): Some directors and senior executives have completed a total shareholding of 0.1978 million shares.
Baolingbao Biology (002286.SZ) announced on August 7th that as of the date of the announcement, some directors and senior management personnel had collectively increased their shareholding by 0.1978 million shares, accounting for 0.0535% of the company's current total share capital. The implementation period of the shareholding plan has expired and has been completed.
Baolingbao Biology: Half-year report for the year 2024.
Baolingbao Biology: Summary of Half-Year Report in 2024.
Baolingbao Biology (002286.SZ): Net income in the first half of the year was 69.33 million yuan, a year-on-year increase of 111.64%.
Baolingbao Biology (002286.SZ) released its semi-annual report, with revenue of 1.186 billion yuan, a 7.49% YoY decrease, net income of 69.33 million yuan, a 111.64% YoY increase, non-GAAP net income of 64.735 million yuan, a 254.96% YoY increase, and EPS of 0.19 yuan.
Market Chatter: Sanyuan Biotech to Boost Supplies of Other Sugar Substitutes Following EU Additional Duties
Pinning Down Baolingbao Biology Co.,Ltd.'s (SZSE:002286) P/E Is Difficult Right Now
No Data
